TPST Insider Trading
Insider Ownership Percentage: 4.70%
Insider Buying (Last 12 Months): $100,001.36
Insider Selling (Last 12 Months): $966,798.90
Tempest Therapeutics Share Price & Price History
Current Price: $0.93
Price Change: ▼ Price Decrease of -0.0062 (-0.67%)
As of 02/14/2025 01:04 PM ET
Tempest Therapeutics Insider Trading History
Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
---|
8/12/2024 | Versant Venture Capital Vi, L. | Major Shareholder | Sell | 387,999 | $1.10 | $426,798.90 | 209,941 | |
8/8/2024 | Versant Venture Capital Vi, L. | Major Shareholder | Sell | 400,000 | $1.35 | $540,000.00 | 597,940 | |
7/3/2024 | Stephen R Brady | CEO | Buy | 35,000 | $2.11 | $73,850.00 | 46,376 | |
7/2/2024 | Samuel Whiting | Insider | Buy | 4,672 | $2.13 | $9,951.36 | 9,573 | |
6/28/2024 | Justin Trojanowski | Insider | Buy | 7,500 | $2.16 | $16,200.00 | 22,168 | |
4/29/2022 | Thomas Woiwode | Director | Buy | 2,118,644 | $2.36 | $4,999,999.84 | 2,118,644 | |
Tempest Therapeutics Institutional Trading History
Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
---|
2/13/2025 | XTX Topco Ltd | 160,807 | $0.13M | 0.0% | +570.3% | 0.368% |  |
2/12/2025 | Geode Capital Management LLC | 354,276 | $0.30M | 0.0% | +61.0% | 0.812% |  |
2/12/2025 | Versant Venture Management LLC | 3,507,055 | $2.93M | 3.4% | N/A | 8.036% |  |
2/11/2025 | Virtu Financial LLC | 43,105 | $36K | 0.0% | N/A | 0.099% |  |
11/16/2024 | Geode Capital Management LLC | 220,067 | $0.31M | 0.0% | +42.7% | 0.873% |  |
11/15/2024 | XTX Topco Ltd | 23,989 | $34K | 0.0% | N/A | 0.095% |  |
11/5/2024 | Empower Advisory Group LLC | 35,000 | $49K | 0.0% | N/A | 0.139% |  |
10/29/2024 | Fullcircle Wealth LLC | 62,000 | $87K | 0.0% | N/A | 0.279% |  |
8/9/2024 | Dimensional Fund Advisors LP | 25,084 | $55K | 0.0% | N/A | 0.113% |  |
5/20/2024 | Virtu Financial LLC | 28,574 | $0.11M | 0.0% | +69.2% | 0.129% |  |
2/15/2024 | MayTech Global Investments LLC | 10,000 | $44K | 0.0% | N/A | 0.052% |  |
8/14/2023 | Rock Springs Capital Management LP | 536,214 | $0.68M | 0.0% | -34.9% | 4.026% |  |
8/11/2023 | Sectoral Asset Management Inc. | 219,394 | $0.28M | 0.0% | N/A | 1.893% |  |
2/14/2022 | Maven Securities LTD | 77,377 | $0.41M | 0.0% | -39.0% | 1.120% |  |
11/15/2021 | Franklin Resources Inc. | 15,240 | $0.22M | 0.0% | N/A | 0.227% |  |
11/12/2021 | Renaissance Technologies LLC | 34,104 | $0.49M | 0.0% | +26.9% | 0.509% |  |
11/9/2021 | BlackRock Inc. | 82,698 | $1.20M | 0.0% | +1,581.2% | 1.234% |  |
11/9/2021 | Monashee Investment Management LLC | 60,000 | $0.87M | 0.2% | -47.2% | 0.896% |  |
8/18/2021 | Ikarian Capital LLC | 89,865 | $1.01M | 0.1% | N/A | 7.076% |  |
8/17/2021 | Boothbay Fund Management LLC | 10,477 | $0.12M | 0.0% | N/A | 0.825% |  |
8/16/2021 | Maven Securities LTD | 106,628 | $1.20M | 0.0% | N/A | 8.396% |  |
8/13/2021 | Renaissance Technologies LLC | 26,867 | $0.30M | 0.0% | N/A | 2.116% |  |
8/13/2021 | Knott David M | 13,833 | $0.16M | 0.1% | N/A | 1.089% |  |
8/13/2021 | Vanguard Group Inc. | 61,150 | $0.68M | 0.0% | N/A | 4.815% |  |
8/13/2021 | FMR LLC | 647,898 | $7.24M | 0.0% | N/A | 51.016% |  |
8/12/2021 | Monashee Investment Management LLC | 113,644 | $1.27M | 0.2% | N/A | 8.948% |  |
5/19/2021 | Squarepoint Ops LLC | 84,879 | $0.10M | 0.0% | N/A | 0.446% |  |
5/17/2021 | Ikarian Capital LLC | 1,348,021 | $1.62M | 0.1% | +897.1% | 7.079% |  |
5/17/2021 | Goldman Sachs Group Inc. | 20,883 | $25K | 0.0% | -50.9% | 0.110% |  |
5/14/2021 | Dimensional Fund Advisors LP | 51,219 | $61K | 0.0% | +259.3% | 0.269% |  |
5/14/2021 | Monashee Investment Management LLC | 500,000 | $0.60M | 0.1% | N/A | 2.626% |  |
5/13/2021 | Barclays PLC | 42,638 | $51K | 0.0% | -90.8% | 0.224% |  |
5/13/2021 | Renaissance Technologies LLC | 924,801 | $1.11M | 0.0% | +66.0% | 4.856% |  |
5/13/2021 | Knott David M | 137,900 | $0.17M | 0.1% | N/A | 0.724% |  |
5/11/2021 | Acadian Asset Management LLC | 291,230 | $0.35M | 0.0% | +189.9% | 1.529% |  |
5/7/2021 | BlackRock Inc. | 139,319 | $0.17M | 0.0% | +9.8% | 0.732% |  |
2/24/2021 | Virtu Financial LLC | 30,755 | $66K | 0.0% | N/A | 0.162% |  |
2/19/2021 | JPMorgan Chase & Co. | 75,264 | $0.16M | 0.0% | +8,328.2% | 0.396% |  |
2/11/2021 | Barclays PLC | 464,390 | $0.99M | 0.0% | +355.7% | 2.444% |  |
2/10/2021 | Renaissance Technologies LLC | 557,108 | $1.19M | 0.0% | +4.1% | 2.932% |  |
2/9/2021 | Bank of New York Mellon Corp | 56,397 | $0.12M | 0.0% | N/A | 0.297% |  |
Data available starting January 2016
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.
Read More on Tempest Therapeutics
Volume
334,594 shs
Average Volume
1,170,107 shs
Market Capitalization
$40.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Who are the company insiders with the largest holdings of Tempest Therapeutics?
Who are the major institutional investors of Tempest Therapeutics?
Which institutional investors are buying Tempest Therapeutics stock?
During the last quarter, TPST stock was purchased by institutional investors including:
- Versant Venture Management LLC
- XTX Topco Ltd
- Geode Capital Management LLC
- Virtu Financial LLC
Within the last year, these company insiders have bought Tempest Therapeutics stock:
- Versant Venture Capital Vi, L (Major Shareholder)
- Stephen R Brady (CEO)
- Justin Trojanowski (Insider)
Learn More investors buying Tempest Therapeutics stock.